Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + sabatolimab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ruxolitinib + sabatolimab is an investigational combination therapy used in clinical studies for patients with myelofibrosis who have a suboptimal response to ruxolitinib alone. Ruxolitinib is a small molecule inhibitor of Janus kinase 1 and Janus kinase 2 (JAK1/JAK2), and is the current standard of care for symptomatic myelofibrosis. Sabatolimab is a monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 (TIM-3), an immune checkpoint molecule expressed on myeloproliferative neoplasm (MPN) progenitor cells. The rationale for the combination is that ruxolitinib suppresses pro-inflammatory cytokine signaling and pathological hematopoietic cell proliferation, while sabatolimab is designed to augment anti-tumor immunity via TIM-3 blockade, potentially improving disease control in MPNs. The combination was studied in the ADORE (NCT04097821) Phase 1b/2 open-label platform trial[2].
- Brand names
- INCYTE INCB18424
- Other names
- ruxolitinib phosphateMBG453MBG-453MBG 453
02
Targets
HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)
Beyond the preview
Go deeper on ruxolitinib + sabatolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + sabatolimab.